RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres

摘要: Treatment options for patients with metastatic colorectal cancer (mCRC) include anti-epithelial growth factor therapies, which, in Europe, are indicated RAS wild-type tumours only and require prior mutation testing of “hot-spot” codons exons 2, 3 4 KRAS NRAS. The aim this study was to evaluate the implementation methods estimate prevalence mCRC patients. Overall, 194 pathology laboratories were invited complete an online survey. Participating asked provide information on their practices aggregated data from 20 30 recently tested mCRC. A total 96 (49.5 %) across 24 European countries completed All participants exon 12 13. Seventy (72.9 %) reported all hot-spot codons, three (3.1 %) 2. Sixty-nine (71.9 %) >80 yearly status. Testing typically performed within reporting institution (93.8 %, n = 90), at request a treating oncologist (89.5 %, n = 85); methodology varied by laboratory individual codon tested. For testing, turnaround times ≤10 working days majority institutions (90.6 %, n = 87). overall crude 48.5 % (95 % confidence interval: 46.4–50.6) codons. Prevalence estimates significantly primary tumour location, approximate number indication given testing. Our findings indicate rapid uptake laboratories.